Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
December 29 2021 - 9:06AM
Business Wire
The amendment expands AditxtScore’s clinical
utility for personalizing the selection of the right treatment for
individuals and monitoring their response to the treatment
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a
biotech innovation company with a mission to improve the health of
the immune system, today announced it had signed an amendment to
its February 3, 2020, Exclusive License Agreement with Stanford
University, extending Aditxt’s exclusive right to license the
technology deployed in AditxtScore™ and securing worldwide
exclusivity in all fields of use of the licensed technology (the
“Technology”).
The Technology is a highly sensitive and accurate method of
detecting and quantifying cellular responses, allowing greater
specificity, quantification, and amplification of clinical and
commercial opportunities. The Technology underpins the AditxtScore™
platform, allowing for a standardization of cellular assays. These
assays can then be used as a development platform for clinical
utility. Applications of the Technology can be used to profile
individuals to select appropriate therapies and assess immune
status before, during, and after therapeutic intervention.
“We are grateful for this continued and expanded license to
apply this Technology to additional fields including organ
transplantation, disease detection, drug development, and vaccine
design,” stated Amro Albanna, Co-Founder and CEO of Aditxt. “Less
than one year ago, we signed this strategic exclusive licensing
agreement. Since then, we have advanced the development of the
Technology, established our AditxtScore Immune Monitoring Center in
Richmond, VA, secured CLIA and CAP accreditation, and became
Medicare licensed,” Albanna added.
About Aditxt™
Aditxt develops technologies focused on improving immune system
health through immune monitoring and reprogramming. Aditxt’s immune
monitoring technology is designed to provide a personalized,
comprehensive system immune system profile. Aditxt’s immune
reprogramming technology, currently preclinical, is designed to
retrain the immune system to induce tolerance to address rejection
of transplanted organs, autoimmune diseases, and allergies.
AditxtScore™ for COVID-19 is Aditxt’s proprietary immune profile
technology to equip people with information about their level of
protection. For more information, please visit: www.aditxt.com and
www.AditxtScore.com
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. All statements other than historical fact
contained in this press release, including, without limitation,
those regarding the execution of a definitive agreement with the
target company and the terms thereof, the completion of the
acquisition and its expected benefits, and statements regarding the
Company’s intentions, beliefs, projections, outlook, analyses, or
current expectations concerning, among other things, the Company’s
ongoing and planned product and business development; the Company’s
intellectual property position; the Company’s ability to develop
commercial functions; expectations regarding product launch and
revenue; the Company’s results of operations, cash needs, spending,
financial condition, liquidity, prospects, growth and strategies;
the industry in which the Company operates; and the trends that may
affect the industry or the Company, are forward-looking statements.
Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section titled “Risk Factors” in the Company’s
most recent Annual Report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other essential factors in the
Company’s other filings with the Securities and Exchange
Commission. All such statements speak only as of the date made. The
Company undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211229005261/en/
Media and Investor Relations Contact: Aditxt, Inc.
ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024